Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial.
Jonas Sundén-CullbergPuran ChenHenrike HäbelPaul SkorupHelena JanolsJohan RasmusonKatarina NiwardÅse Östholm BalkhedKaterina ChatzidionysiouHilmir AsgeirssonOla BlennowÅsa ParkeAnna-Karin SvenssonJagadeeswara Rao MuvvaHans-Gustav Ljunggrennull nullAnna-Carin HorneUlrika ÅdénJan-Inge HenterAnders SönnerborgJan VesterbackaPiotr NowakJon LampaPublished in: PloS one (2023)
Premature closure of trial precludes firm conclusions. Anakinra or tocilizumab did not significantly shorten time to clinical recovery compared to usual care. (IMMCoVA, NCT04412291, EudraCT: 2020-00174824).
Keyphrases
- phase iii
- open label
- phase ii
- study protocol
- rheumatoid arthritis
- clinical trial
- healthcare
- juvenile idiopathic arthritis
- coronavirus disease
- rheumatoid arthritis patients
- sars cov
- palliative care
- randomized controlled trial
- quality improvement
- emergency department
- pain management
- disease activity
- acute care
- double blind
- chronic pain
- placebo controlled